Staar Surgical
STAA
22.31
-0.05
-0.22%
Staar Surgical
US · STAA
#3168 by market cap
22.31
-0.05
-0.22%
Live - 5344 symbols - heartbeat 273s ago
· 2026-10-08 10:10
Pre-market
22.00
-1.61%
After-hours
22.36
0.00%
- Market cap
- 1.12B
- P/E (TTM)i
- 278.88
- P/Bi
- 3.06
- EPSi
- -1.62
- Div yieldi
- 0.00%
- 52W posi
- 33%
Reader sentiment
Are you bullish or bearish on STAA?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 2 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.4 percentage points.
Institutional ownership
- Held by institutions
- 110.86% -0.42pp
- Institutions
- 243 +2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Hedge Fund61.72%
Mutual Fund39.81%
Public Company6.93%
Individual/Insider0.89%
Government Pension Fund0.82%
Sovereign Wealth Fund0.73%
Private Company0.45%
Insurance Company0.29%
Top holders as of 2026-06-30
Broadwood Capital, Inc.
32.16% · 16.12M sh
BlackRock
13.42% · 6.73M sh
Madison Avenue Partners, LP
8.33% · 4.18M sh
Yunqi Capital Limited
6.50% · 3.26M sh
Point72 Asset Management, L.P.
4.86% · 2.44M sh
The Goldman Sachs Group, Inc.
4.07% · 2.04M sh
Vanguard Portfolio Management, LLC
3.95% · 1.98M sh
Vanguard Capital Management, LLC
3.74% · 1.87M sh
State Street Global Advisors
3.53% · 1.77M sh
Anatole Investment Management Limited
3.29% · 1.65M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 38 buys · 11 sells
| Name | Role | Stake |
|---|---|---|
| Broadwood Capital, Inc. | -- | 32.16% |
| Warren Foust | Chief Operating Officer | 0.19% |
| Stephen Farrell | Lead Independent Director | 0.16% |
| Wei Jiang | Independent Director | 0.15% |
| Magda Michna | Chief Clinical, Regulatory & Medical Affairs Officer | 0.08% |
| Deborah Andrews | Former Chief Financial Officer | 0.08% |
| Nathaniel Sisitsky | General Counsel | 0.06% |
| Neal Bradsher | Director | 0.05% |
| Richard LeBuhn | Director | 0.04% |
| Louis Silverman | Former Independent Chairperson | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-13 | Deborah Andrews | Former Chief Financial Officer | Derivative Exercise and Sale | -2,662 | $26.18 |
| 2026-08-13 | Deborah Andrews | Former Chief Financial Officer | Other Derivative Acquisition | +4,975 | -- |
| 2026-08-13 | Deborah Andrews | Former Chief Financial Officer | Other Derivative Acquisition | +8,952 | $26.18 |
| 2026-08-13 | Deborah Andrews | Former Chief Financial Officer | Other Derivative Acquisition | +29,159 | $26.18 |
| 2026-08-13 | Deborah Andrews | Former Chief Financial Officer | Derivative Exercise and Retained | +2,571 | -- |
| 2026-08-13 | Magda Michna | Chief Clinical, Regulatory & Medical Affairs Officer | Derivative Exercise and Sale | -3,356 | $26.18 |
| 2026-08-13 | Magda Michna | Chief Clinical, Regulatory & Medical Affairs Officer | Derivative Exercise and Retained | +3,243 | $26.18 |
| 2026-08-13 | Warren Foust | Chief Operating Officer | Derivative Exercise and Sale | -5,595 | $26.18 |
| 2026-08-13 | Warren Foust | Chief Operating Officer | Other Derivative Acquisition | +22,493 | -- |
| 2026-08-13 | Warren Foust | Chief Operating Officer | Other Derivative Acquisition | +78,433 | $26.18 |
| 2026-08-13 | Warren Foust | Chief Operating Officer | Other Derivative Acquisition | +255,489 | $26.18 |
| 2026-08-13 | Warren Foust | Chief Operating Officer | Derivative Exercise and Retained | +5,402 | -- |
| 2026-07-30 | Deborah Andrews | Former Chief Financial Officer | Derivative Exercise and Sale | -17,056 | $24.36–31.21 |
| 2026-07-30 | Deborah Andrews | Former Chief Financial Officer | Derivative Exercise and Retained | +17,686 | -- |
| 2026-07-30 | Warren Foust | Chief Operating Officer | Derivative Exercise and Sale | -10,576 | $24.36 |
| 2026-07-30 | Warren Foust | Chief Operating Officer | Derivative Exercise and Retained | +10,211 | -- |
| 2026-06-17 | Louis Silverman | Former Independent Chairperson | Other Derivative Acquisition | +6,182 | -- |
| 2026-06-17 | Louis Silverman | Former Independent Chairperson | Derivative Exercise and Retained | +10,683 | -- |
| 2026-06-17 | Neal Bradsher | Director | Other Derivative Acquisition | +11,145 | $29.12 |
| 2026-06-17 | Lilian Zhou | Director | Other Derivative Acquisition | +3,091 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 10:10:08 · For reference only, not investment advice and not tailored to your situation.